Word: yeasting
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
CuraGen of New Haven, Conn., is one of the innovative firms that have refined this art. Its proprietary technology--an adaptation of a decade-old technique--allows CuraGen's scientists to put human genes into yeast cells and effectively "fish" for proteins relevant to drug discovery. "We learned at the seat of the inventor of this technology," boasts technology group leader Bruce Taillon, "and showed him what would happen when CuraGen was set loose on it." The company stunned the biotech world in January, when it announced a 15-year, $1.4 billion deal with Bayer to develop drugs against obesity...
...boys sleep on piled-up blankets, their few clothes dangling from nails. In the room that passes for a kitchen, two paraffin burners sit on the dirt floor alongside the month's food: four cabbages, a bag of oranges and one of potatoes, three sacks of flour, some yeast, two jars of oil and two cartons of milk. Next to a dirty stack of plastic pans lies the mealy meal and rice that will provide their main sustenance for the month. A couple of bars of soap and two rolls of toilet paper also have to last the month. Tsepho...
...comforting tone will soothe even the nervous novice: "It's only flour and water and time," she insists. But a look through these pages shows that when Glezer bakes, it's actually high art. If anything is going to persuade time-starved American cooks to pick up the yeast, it will be this breathtaking opus...
Meanwhile, the dietary-supplement industry got into the act after it discovered that Chinese red yeast fermented on rice contains small amounts of the same active ingredient found in lovastatin (Mevacor). The FDA tried to ban the supplement's sale in the U.S., but the action has become the subject of a lengthy court process. The controversy hasn't stopped Merck, which manufactures Mevacor and Zocor, and Bristol-Myers Squibb, which produces Pravachol, from arguing that they should be allowed to sell their pharmaceutical-grade products at similarly low doses to the general public...
...first report emphasized that we should begin by sequencing the relatively tiny genomes (1 million to 13 million letters) of bacteria and yeast and then move on to the 100 million-letter-size genomes of worms and flies. We were confident that by the time we were done, sequencing technology would cost less than 50[cents] a letter, and that by then, we would be ready to tackle the human genome. We were also confident that genomics would pay scientific and medical dividends long before the final letters of the human genome were in place...